$3.85
1.79% yesterday
Nasdaq, Nov 15, 10:09 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Tango Therapeutics Inc Classifications & Recommendation:

Buy
100%

Tango Therapeutics Inc Price Target

Target Price $11.50
Price $3.85
Potential
Number of Estimates 8
8 Analysts have issued a price target Tango Therapeutics Inc 2025 . The average Tango Therapeutics Inc target price is $11.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 9 Analysts recommend Tango Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Tango Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Tango Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 36.53 46.01
46.94% 25.94%
EBITDA Margin -305.94% -314.28%
28.95% 2.73%
Net Margin -317.55% -278.61%
40.25% 12.26%

9 Analysts have issued a sales forecast Tango Therapeutics Inc 2024 . The average Tango Therapeutics Inc sales estimate is

$46.0m
Unlock
. This is
6.05% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$53.6m 23.56%
Unlock
, the lowest is
$43.0m 0.88%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $36.5m 46.94%
2024
$46.0m 25.94%
Unlock
2025
$29.3m 36.23%
Unlock
2026
$28.6m 2.62%
Unlock
2027
$89.9m 214.61%
Unlock
2028
$34.7m 61.41%
Unlock

1 Analyst has issued an EBITDA forecast Tango Therapeutics Inc 2024 . The average Tango Therapeutics Inc EBITDA estimate is

$-145m
Unlock
. This is
5.38% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-145m 5.38%
Unlock
, the lowest is
$-145m 5.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-112m 4.41%
2024
$-145m 29.37%
Unlock
2025
$-225m 55.93%
Unlock
2026
$-254m 12.80%
Unlock

EBITDA Margin

2023 -305.94% 28.95%
2024
-314.28% 2.73%
Unlock
2025
-768.45% 144.51%
Unlock
2026
-890.20% 15.84%
Unlock

3 Tango Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Tango Therapeutics Inc net profit estimate is

$-128m
Unlock
. This is
2.00% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-125m 0.85%
Unlock
, the lowest is
$-130m 3.42%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-116m 12.20%
2024
$-128m 10.50%
Unlock
2025
$-153m 19.27%
Unlock
2026
$-155m 1.41%
Unlock
2027
$-156m 0.81%
Unlock
2028
$-87.0m 44.33%
Unlock

Net Margin

2023 -317.55% 40.25%
2024
-278.61% 12.26%
Unlock
2025
-521.08% 87.03%
Unlock
2026
-542.64% 4.14%
Unlock
2027
-173.88% 67.96%
Unlock
2028
-250.84% 44.26%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.08 -1.19
12.20% 10.19%
P/E negative
EV/Sales 3.43

3 Analysts have issued a Tango Therapeutics Inc forecast for earnings per share. The average Tango Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.19
Unlock
. This is
1.71% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.16 0.85%
Unlock
, the lowest is
$-1.21 3.42%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.08 12.20%
2024
$-1.19 10.19%
Unlock
2025
$-1.42 19.33%
Unlock
2026
$-1.44 1.41%
Unlock
2027
$-1.46 1.39%
Unlock
2028
$-0.81 44.52%
Unlock

P/E ratio

Current -3.29 56.25%
2024
-3.23 1.82%
Unlock
2025
-2.70 16.41%
Unlock
2026
-2.67 1.11%
Unlock
2027
-2.65 0.75%
Unlock
2028
-4.75 79.25%
Unlock

Based on analysts' sales estimates for 2024, the Tango Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.64 74.20%
2024
3.43 5.70%
Unlock
2025
5.38 56.81%
Unlock
2026
5.53 2.69%
Unlock
2027
1.76 68.21%
Unlock
2028
4.55 159.14%
Unlock

P/S ratio

Current 9.53 57.96%
2024
8.99 5.71%
Unlock
2025
14.10 56.81%
Unlock
2026
14.48 2.69%
Unlock
2027
4.60 68.21%
Unlock
2028
11.92 159.14%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today